Human Endogenous Retrovirus E (HERV-E)

Human Endogenous Retrovirus E (HERV-E) is a member of the class I endogenous retrovirus family, representing genetic remnants of ancient retroviral infections integrated into the human germline. In most healthy tissues, HERV-E is epigenetically silenced through DNA methylation and histone modifications. However, it is selectively reactivated in certain malignancies, most notably clear cell renal cell carcinoma (ccRCC), where the loss of the von Hippel-Lindau (VHL) tumor suppressor leads to HIF-mediated activation of the HERV-E long terminal repeat (LTR). This tumor-specific expression, particularly of the provirus located on chromosome 6q15, produces immunogenic antigens such as the CT-RCC-1 peptide. Because of its high specificity for tumor cells, HERV-E has become a prominent target for novel immunotherapies, including T-cell receptor (TCR) engineered T cells and cancer vaccines. Clinical and preclinical studies have demonstrated that T cells targeting HERV-E can mediate the regression of established tumors in models of metastatic kidney cancer. Additionally, epigenetic modulators like DNA methyltransferase inhibitors are being explored to enhance HERV-E expression and trigger a 'viral mimicry' state, which stimulates the innate immune system to recognize cancer cells as infected. While therapeutic challenges such as T-cell persistence remain, HERV-E represents a promising candidate for precision oncology in HLA-matched patients.

Other names

CT-RCC HERV-EHERV-E 6q15Human endogenous retrovirus type EERV-E

Adoptive T-cell therapy targeting HERV-E-derived antigens; Epigenetic reactivation to induce viral mimicry and innate immune signaling